ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LQDA / forecast
ARQT (54) ABCL (44) INDV (51) LEGN (60) ⌘ Pro Terminal →

Liquidia Corporation (LQDA) 12-Month Stock Forecast & Price Target Cone

$45.06 +0.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.99

Liquidia Corporation (LQDA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $4.03B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LQDA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LQDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Liquidia Corporation (NASDAQ: LQDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $45.06 (+0.16% 1D, market cap $4.03B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, LQDA ranks #557 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LQDA compare to ARQT and ABCL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LQDA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -12.6%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and ABCL (AbCellera Biologics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -20.5%, cap $3.97B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LQDA?
▼

Per LQDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819576), Liquidia Corporation generated $158.3M in revenue (+1031.2% YoY), -$68.9M in net income, and -$40.0M in free cash flow against $327.9M in total assets and $127.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $44.99 (-0.16%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Cash (9)Whales (7)SEC (11)Macro (3)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$98 Bull$41 Base$32 Bear
📬 FREE LQDA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LQDA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY LQDA SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (31% of score)

Altman Z-Score 6.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (52.5) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
28
Grade E$33.94+14.5% Next Q
Q2 (-2Q)
31
Grade E$38.86+17.7% Next Q
Q3 (-1Q)
33
Grade E$45.72-1.4% Next Q
Current
36
Grade D-$45.06-8.3% Hist 90D α
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LQDA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LQDA currently carries a cautious 36/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.50) and Max Pain ($47.31) forces dealer call-delta covering toward $98.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LQDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LQDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LQDA Position Size: $10,000

Shares at $45.06: 221.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $31.67
$7,028
$-2,972 (-29.7%)
12M Consensus BaseTarget $40.60
$9,010
$-990 (-9.9%)
12M Bull Case BreakoutTarget $98.29
$21,813
+$11,813 (+118.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$4274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$9269%B
JP MorganUS Large-Cap ResearchSELL$3658%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LQDA)

  • ✓Walkthrough of LQDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LQDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +17.10%▼ DESCENDING CHANNEL
2026-11-03O $44.99H $45.06L $44.99C $45.06VOL 2.09M
RES: $64.92SUP: $13.42SMA50: $51.50SMA200: $54.39
$98.60$77.92$57.25$36.57$15.89RES $64.92SUP $13.42$45.062026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LQDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LQDA Butterfly Map → + Track LQDA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
14.6%/yr Implied 5Y Growth

vs. +1031.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LQDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LQDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LQDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LQDA)

Health Care Rank #557 of 1015 ⚔️ ARQT vs LQDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LQDA vs. ARQT, ABCL, INDV, LEGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Liquidia Corporation (LQDA) ranks #557 by composite RQD confidence (36/100, grade D-) and #178 by equity capitalization ($4.03B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with LQDA at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LQDA ACTIVE
Liquidia Corporation
D- 36/100 — — -12.6% +0.16% $4.03B Benchmark Subject
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 — 90.2% -3.0% +0.31% $4.03B /arqt-vs-lqda →
ABCL
AbCellera Biologics Inc.
D 44/100 — — -20.5% -6.19% $3.97B /abcl-vs-lqda →
INDV
Indivior Pharmaceuticals Inc.
D 51/100 19.8x 80.2% 62.2% +0.34% $4.17B /indv-vs-lqda →
LEGN
Legend Biotech Corporation
C- 60/100 32.8x — 9.9% -3.00% $4.21B /legn-vs-lqda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001819576 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Liquidia Corporation (LQDA) reported GAAP revenue of $158.3M (+1031.2% vs. FY2024 revenue of $14.0M , and +805.3% cumulative change since FY2023) , GAAP net income of -$68.9M, operating cash flow of -$35.7M, and free cash flow of -$40.0M (+59.3% YoY). On the balance sheet, LQDA closed FY2025 with $327.9M in total assets against $127.4M in total debt (Altman Z-Score: 6.33, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $158.3M -$68.9M -$35.7M -$40.0M $327.9M $127.4M
FY2024 (FY) 2024-12-31 $14.0M -$130.4M -$93.4M -$98.4M $230.3M $67.9M
FY2023 (FY) 2023-12-31 $17.5M -$78.5M -$41.6M -$42.4M $2.21B $518.3M

3. LQDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LQDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Liquidia Corporation (NASDAQ: LQDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $45.06 (+0.16% 1D, market cap $4.03B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, LQDA ranks #557 in composite RQD confidence.

How does LQDA compare to ARQT and ABCL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LQDA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -12.6%. By comparison, ARQT (Arcutis Biotherapeutics Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -3.0%, cap $4.03B) and ABCL (AbCellera Biologics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -20.5%, cap $3.97B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LQDA?

Per LQDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001819576), Liquidia Corporation generated $158.3M in revenue (+1031.2% YoY), -$68.9M in net income, and -$40.0M in free cash flow against $327.9M in total assets and $127.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LQDA trading relative to its 50-day, 200-day, and 52-week technical levels?

LQDA last traded at $45.06 (+0.16% on volume of 2,091,818 shares), positioning the stock -12.50% below its 50-day simple moving average ($51.50) and -17.15% below its 200-day simple moving average ($54.39). Across its 52-week range of $22.21 to $93.61, LQDA sits at the 32.0% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($39.43 to $50.69).

Direct Sub-Reports: LQDA RQD Cockpit LQDA 12M Forecast LQDA Earnings & Move LQDA Dividends & DRIP LQDA Insiders & 13F LQDA Whale Options LQDA Profit Sankey LQDA News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LQDA — Liquidia Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Liquidia Corporation (LQDA) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $45.06 (+0.16% 1D, market capitalization $4.03B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -12.6%, gross margin of —, operating margin of -32.5%, and free cash flow yield of -0.99%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (11/20): Incorporates a 0.90x equity beta, Altman Z-Score of 6.33, Piotroski F-Score of 5/9, and Debt/Equity of 2.66x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Liquidia Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Liquidia Corporation (LQDA) reported $158.3M in annual revenue (up from $14.0M in FY2024, +1031.2% YoY) and -$68.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($17.5M revenue, -$78.5M net income) through FY2025, LQDA scaled operating cash flow to -$35.7M and free cash flow to -$40.0M, backed by $327.9M in total assets against $127.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.99% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $22.21 – $93.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -32.5% operating margins and a 0.90x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LQDA carries a macro regime beta of 0.90 and gross margin of —.

  • Key Question #1: Can LQDA sustain or expand its -32.5% operating margin and -12.6% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $158.3M and free cash flow of -$40.0M, how will capital allocation balance growth reinvestment against $127.4M in total debt?
  • Key Question #3: How sensitive is LQDA's 21.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?

LQDA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Liquidia Corporation (LQDA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LQDA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LQDA Bull vs. Bear Conversation Board — What's Your Call at $45.06?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LQDA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LQDA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $52.27 (+16.0%)
📌 Pinned Debate

A $380.7M litigation settlement with United Therapeutics drove a reported 40%+ share surge and a raised $53.5 price target, with FY 202

Picked up a starter position in LQDA in my $100K Virtual Cash book at $45.06. A $380.7M litigation settlement with United Therapeutics drove a reported 40%+ share surge and a raised $53.5 price target, with FY 2025 revenue rising to $158.3M from $14.0M.. Trading inside a $22.31–$93.61 52-week range with -0.99% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 7/20 institutional whale-flow stock at $45.06 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $36.05 (-20.0%)
Spot @ $45.06

Per the RQD rating, ROIC of -12.6%, FCF yield of -0.99%, and Debt/Equity of 2.66 leave the business unprofitable and leveraged with a w

Careful chasing LQDA at $45.06. Per the RQD rating, ROIC of -12.6%, FCF yield of -0.99%, and Debt/Equity of 2.66 leave the business unprofitable and leveraged with a weak 36/100 score.. Gross margin is 0.0%, but operating margin is -32.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $36.05 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%